Status:
COMPLETED
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Lead Sponsor:
Rennes University Hospital
Conditions:
Glioblastoma, Adult
Eligibility:
All Genders
18-79 years
Phase:
PHASE3
Brief Summary
Fluorescence guidance is a safe and efficient tool for glioblastomas resection. The most widely used technique is based on 5-aminolevulinic acid (5ala), which stains glioblastoma cells through a metab...
Eligibility Criteria
Inclusion
- Age between 18 and 79
- Karnofsky index \> 70 %
- Brain MRI showing a parenchymal lesion with typical features of glioblastoma, \< 1week
- Achievable gross total removal, as assessed by the neurosurgical staff
- Written consent
Exclusion
- Contraindication to fluorescein
- Contraindication to MRI
- History of brain surgery \<6 months
- Guardianship, tutelage or deprivation of liberty
- Pregnancy or breastfeeding
- Participation to other interventional clinical studies
Key Trial Info
Start Date :
October 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 18 2022
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT03291977
Start Date
October 5 2017
End Date
January 18 2022
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Rennes
Rennes, France